Vol 9 (2024): Continuous Publishing
Review paper
Published online: 2024-05-02

open access

Page views 62
Article views/downloads 30
Get Citation

Connect on Social Media

Connect on Social Media

Therapy options for ocular basal cell carcinoma — possibilities and limitations

Piotr Jakub Gaca1, Robert Rejdak1, Beata Flis1, Aleksandra A. Lipczyńska2, Maja Nowak3, Michał Lewandowicz4, Rafał Nowak3
Ophthalmol J 2024;9:37-44.

Abstract

Basal cell carcinoma (BCC) stands as one of the most prevalent malignant epithelial skin tumors worldwide, and it is characterized by diverse clinical forms with locally destructive growth and a high recurrence rate. Usually, this type of cancer is more common in individuals over the age of 60. Therefore, the current study discusses contemporary approaches to treating basal cell carcinoma, highlighting the advantages and disadvantages of potential therapeutic options.

Article available in PDF format

View PDF Download PDF file

References

  1. Holbach L, Cursiefen C, Junemann A, et al. Differential eyelid tumor diagnosis. Ophthalmologe. 2002; 99(quiz412–393): 394–411.
  2. Kakkassery V, Loeffler KU, Sand M, et al. [Current diagnostics and therapy recommendations for ocular basal cell carcinoma]. Ophthalmologe. 2017; 114(3): 224–236.
  3. Rokohl AC, Kopecky A, Guo Y, et al. Surgical resection with ophthalmoplastic reconstruction: Gold standard in periocular basal cell carcinoma. Ophthalmologe. 2020; 117: 95–105.
  4. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019; 80(2): 303–317.
  5. McDaniel B, Badri T, Steele RB. Basal Cell Carcinoma. StatPearls [Internet], Treasure Island (FL) 2023.
  6. Rokohl AC, Loser H, Mor J, et al. Young male patient with unusual space-occupying lesion of the lower eyelid. Ophthalmologe. 2020; 117: 73–77.
  7. Kappelin J, Green AC, Ingvar Å, et al. Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. Br J Dermatol. 2022; 186(6): 963–969.
  8. Snarskaya ES, Olisova OY, Ibrahim A, et al. Modern approaches to the treatment of basal cell carcinoma from dermatologists’ point of view. MOJ Tumor Res. 2018; 1(2): 48–51.
  9. Rutkowski P, Owczarek W, Nejc D, et al. Skin carcinomas. Oncol Clin Pract. 2020; 16(4): 143–162.
  10. Krajowy Rejestr Nowotworów. www.onkologia.org.pl.
  11. Bologni JL, Jorizzo JL, Schaffer JV. Dermatology. Elsevier Saunders 2012.
  12. Reinau D, Surber C, Jick SS, et al. Epidemiology of basal cell carcinoma in the United Kingdom: incidence, lifestyle factors, and comorbidities. Br J Cancer. 2014; 111(1): 203–206.
  13. Saleh GM, Desai P, Collin JR, et al. Incidence of eyelid basal cell carcinoma in England: 2000-2010. Br J Ophthalmol. 2017; 101(2): 209–212.
  14. Weiling M, Bergua A, Kruse FE, et al. [Therapy options for malignant eyelid tumors]. Ophthalmologe. 2016; 113(12): 1095–1108.
  15. Mohs FE, Mohs FE. Chemosurgery of the microscopically controlled excision of skin cancer. Proc Natl Cancer Conf. 1970; 6(3): 517–527.
  16. Sun MT, Wu A, Figueira E, et al. Management of periorbital basal cell carcinoma with orbital invasion. Future Oncol. 2015; 11(22): 3003–3010.
  17. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015; 88(2): 167–179.
  18. Malhotra R, Huilgol SC, Huynh NT, et al. The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years. Ophthalmology. 2004; 111(4): 624–630.
  19. Malhotra R, Huilgol SC, Huynh NT, et al. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology. 2004; 111(4): 631–636.
  20. Gaca PJ, Rejdak R, Lewandowicz M, et al. Surgical excision of eyelid tumors and subsequent ophthalmoplastic reconstruction. Die Ophthalmologie. 2023; 121(S1): 23–32.
  21. Sabu DM, Kroes J, Gilham C, et al. Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma. Curr Probl Cancer. 2021; 45(6): 100736.
  22. Rubin AI, Chen EH, Ratner D. Basal-Cell Carcinoma. N Engl J Med. 2005; 353(21): 2262–2269.
  23. Basset-Seguin N, Herms F. Update in the Management of Basal Cell Carcinoma. Acta Derm Venereol. 2020; 100(11): adv00140.
  24. Su MG, Potts LB, Tsai JH. Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib. Am J Ophthalmol Case Rep. 2020; 19: 100755.
  25. Yin VT, Merritt HA, Sniegowski M, et al. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015; 33(2): 159–169.
  26. Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol. 2005; 53(3): 458–463.
  27. Kalaghchi B, Esmati E, Ghalehtaki R, et al. High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region: preliminary results of a prospective single institution study. J Contemp Brachytherapy. 2018; 10(2): 115–122.
  28. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. 1992; 18(7): 549–554.
  29. Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer. 2003; 98(12): 2708–2714.
  30. Boaventura P, Pereira D, Mendes A, et al. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. J Dermatol Sci. 2014; 73(1): 31–39.
  31. Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment. Onco Targets Ther. 2017; 10: 2483–2489.
  32. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984; 10(6): 1043–1060.
  33. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23): 2171–2179.
  34. Carpenter RL, Ray H. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer. Drug Saf. 2019; 42(2): 263–279.
  35. Leavitt E, Lask G, Martin S. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma. Curr Treat Options Oncol. 2019; 20(11): 84.
  36. Fania L, Didona D, Morese R, et al. Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2020; 8(11).
  37. Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013; 14(7): 416–429.
  38. Hanna A, Shevde LA. Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. Mol Cancer. 2016; 15: 24.
  39. Ju X, Gaca P, Fan W, et al. Therapy Failure and Resistance Mechanism in Eyelid and Ocular Surface Tumors. Neurosignals. 2022; 30(S1): 21–38.
  40. Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020; 34(9): 1944–1956.
  41. Brancaccio G, Pea F, Moscarella E, et al. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma. Front Oncol. 2020; 10: 582866.
  42. Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16(6): 729–736.
  43. Papastefanou VP, René C. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion. Ophthalmic Plast Reconstr Surg. 2017; 33(3S Suppl 1): S68–S70.
  44. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012; 148(11): 1324–1325.
  45. Danial C, Sarin KY, Oro AE, et al. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res. 2016; 22(6): 1325–1329.
  46. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014; 70(1): 60–69.
  47. Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015; 9(2): 389–397.
  48. Kuonen F, Huskey NE, Shankar G, et al. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. J Invest Dermatol. 2019; 139(7): 1439–1448.